血必净在门静脉高压症术后的应用  

Postoperative application of xuebijing in portal hypertension

作　　者：叶勇[1] 马金良[2] 余继海[2] 许戈良[2] 李建生[2] 荚卫东[2] 

机构地区：[1]安徽省立医院急诊外科,安徽合肥230001 [2]安徽省立医院肝胆胰外科,安徽合肥230001

出　　处：《安徽医药》2015年第1期82-86,共5页Anhui Medical and Pharmaceutical Journal

基　　金：安徽省"115"产业创新团队资助项目(No 1208085MH133);2010年安徽省卫生厅医学科研重点项目(No2010B008)

摘　　要：目的探讨血必净在门静脉高压症断流术后应用的效果。方法在该院近2年诊断为肝炎后门静脉高压症接受脾切除+断流术治疗的患者中选择46例随机分为研究组和对照组,研究组术后使用血必净,对照组术后常规治疗。检测两组术前及术后1、3、5、7 d肝功能指标、凝血功能指标、免疫指标、炎症反应指标并观察术后并发症。结果两组患者术后结合胆红素(DBil)、凝血酶原时间(PT)、T淋巴细胞亚群CD4+、CD8+、免疫球蛋白Ig G、Ig M、C反应蛋白(CRP)及门静脉血栓发生例数差异有统计学意义(P<0.05)。结论门静脉高压症患者术后使用血必净可提高机体免疫力、减轻炎症反应、减少术后并发症及门静脉血栓的发生率。Objective To investigate the effects of Xuebijing in patients of portal hypertension after devascularization operations.Meth-ods Forty-six patients of devascularization were randomized into two groups：group A was Xuebijing treatment group （n =23）,and group B was conventional treatment group （n =23）.Preoperative and postoperative 1,3,5,7 d ALT,PT,TBIL,CRP,PVT and other in-dicators of patients in both groups were detected to determine the recovery of liver function.Results The total number of cases of post-operative differences in the two groups of bilirubin （DBil）,prothrombin time （PT）,T lymphocyte subsets CD4 ＋、CD8 ＋,immunoglobu-lins IgG,IgM,C-reactive protein （CRP）and portal vein thrombosis there was statistically significant （P 〈0.05）.Conclusions Post-operative patients with portal hypertension using Xuebijing can improve immunity,reduce inflammation,reduce postoperative complica-tions and the incidence of portal vein thrombosis.

关 键 词：门静脉高压症 断流术 血必净 

分 类 号：R657.34[医药卫生—外科学]